AzTrials
AzTrials

Infections, MeningococcalPhase 3NCT03621670

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

A Phase 3 study testing Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13 and Pediarix in people with Infections, Meningococcal, run by GlaxoSmithKline at 57 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccinesv(RIV). Read more about this study

Who is it for?
Ages 6 to 12 weeksHealthy volunteers can take part
Conditions the study is for
Infections, Meningococcal
What is being tested?
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13 and Pediarix
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
1,196 participants
Where
57 sitesin 2 countries
Study dates
27 Jul 2018to 27 Dec 2024
Phase
Phase 3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 12 weeks
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • All subjects must satisfy all the following criteria at study entry:
  • Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the eDiary, return for follow-up visits).
  • Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.
  • A male or female between, and including, 42 and 84 days of age (i.e., 6 through 12 weeks) at the time of the 1st vaccination.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Born full-term (i.e. after a gestation period of ≥ 38 weeks).

Who cannot join

  • If any exclusion criterion applies, the subject must not be included in the study:
  • Child in care
  • Each subject must not have:
  • Progressive, unstable or uncontrolled clinical conditions.
  • Hypersensitivity, including allergy to any component of vaccines, medicinal product or medical equipment whose use is foreseen in this study.
  • Hypersensitivity to latex.
Show all 24Show fewer
  • Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
  • Abnormal function of the immune system resulting from:
  • Clinical conditions.
  • Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days from birth.
  • Administration of antineoplastic and immunomodulating agents or radiotherapy for any duration from birth.
  • Autoimmune disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders; lupus erythematosus and associated conditions; rheumatoid arthritis and associated conditions; scleroderma and associated disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes).
  • Received immunoglobulins or any blood products from birth.
  • Received an investigational or non-registered medicinal product from birth.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.
  • Neuroinflammatory disorders (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital and peripartum neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalised tonic-clonic seizures, partial complex seizures, partial simple seizures or febrile convulsions).
  • Congenital or peripartum disorders resulting in a chronic condition (including but not limited to: chromosomal abnormalities, cerebral palsy, metabolism or synthesis disorders, cardiac disorders).
  • Study personnel as an immediate family or household member.
  • Current or previous, confirmed or suspected disease caused by N. meningitidis
  • Household contact with and/or intimate exposure from birth to an individual with laboratory confirmed N. meningitidis and/or Streptococcus pneumoniae infection or colonization.
  • Previous administration of meningococcal B or pneumococcal vaccine at any time prior to informed consent.
  • Received a dose of DTPa-HBV-IPV, HRV, MMR, VV and/or Hib at any time prior to informed consent. Receipt of one dose of HBV up to 4 weeks prior to informed con-sent is allowed.
  • Serious chronic illness.
  • Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for Intussusception (IS).

Trial locations and contacts

57 sites in 2 countries.

57 sites in 2 countries

United States56 sites

  • GSK Investigational Site

    Anaheim, California, 92804

  • GSK Investigational Site

    Baltimore, Maryland, 21021

  • GSK Investigational Site

    Bardstown, Kentucky, 40004

  • GSK Investigational Site

    Beaumont, Texas, 77706

  • GSK Investigational Site

    Bingham Farms, Michigan, 48025

  • GSK Investigational Site

    Birmingham, Alabama, 35205

  • GSK Investigational Site

    Boone, North Carolina, 28607

  • GSK Investigational Site

    Bryan, Texas, 77802

  • GSK Investigational Site

    Charleston, South Carolina, 29406

  • GSK Investigational Site

    Cincinnati, Ohio, 45245

  • GSK Investigational Site

    Clarksville, Tennessee, 37040

  • GSK Investigational Site

    Dayton, Ohio, 45406

  • GSK Investigational Site

    Dayton, Ohio, 45414

  • GSK Investigational Site

    Edinburg, Texas, 78504

  • GSK Investigational Site

    Fairfield, Ohio, 45014

  • GSK Investigational Site

    Fall River, Massachusetts, 02721

  • GSK Investigational Site

    Fayetteville, Arkansas, 72703

  • GSK Investigational Site

    Hermitage, Pennsylvania, 16148

  • GSK Investigational Site

    Houston, Texas, 77065

  • GSK Investigational Site

    Houston, Texas, 77090

  • GSK Investigational Site

    Jonesboro, Arkansas, 72401

  • GSK Investigational Site

    Kansas City, Missouri, 64108

  • GSK Investigational Site

    Kingsport, Tennessee, 37660

  • GSK Investigational Site

    Lake Mary, Florida, 32746

  • GSK Investigational Site

    Layton, Utah, 84041

  • GSK Investigational Site

    Lincoln, Nebraska, 68516

  • GSK Investigational Site

    Liverpool, New York, 13090

  • GSK Investigational Site

    Louisville, Kentucky, 40202

  • GSK Investigational Site

    Louisville, Kentucky, 40207

  • GSK Investigational Site

    Louisville, Kentucky, 40291

  • GSK Investigational Site

    Marshfield, Wisconsin, 54449

  • GSK Investigational Site

    Miami, Florida, 33142

  • GSK Investigational Site

    Nampa, Idaho, 83686

  • GSK Investigational Site

    Nampa, Idaho, 83702

  • GSK Investigational Site

    Newton, Kansas, 67114

  • GSK Investigational Site

    Oakland, California, 94611

  • GSK Investigational Site

    Omaha, Nebraska, 68128

  • GSK Investigational Site

    Orem, Utah, 84057

  • GSK Investigational Site

    Pittsburgh, Pennsylvania, 15224

  • GSK Investigational Site

    Provo, Utah, 84604

  • GSK Investigational Site

    Raleigh, North Carolina, 27609

  • GSK Investigational Site

    Richmond, Virginia, 23298

  • GSK Investigational Site

    Roseville, California, 95661

  • GSK Investigational Site

    Roy, Utah, 84067

  • GSK Investigational Site

    Salt Lake City, Utah, 84121

  • GSK Investigational Site

    San Antonio, Texas, 78229

  • GSK Investigational Site

    San Antonio, Texas, 78244

  • GSK Investigational Site

    Sioux Falls, South Dakota, 57105

  • GSK Investigational Site

    South Euclid, Ohio, 44121

  • GSK Investigational Site

    Spokane, Washington, 99202

  • GSK Investigational Site

    Syracuse, New York, 13210

  • GSK Investigational Site

    Syracuse, Utah, 84075

  • GSK Investigational Site

    Tampa, Florida, 33613

  • GSK Investigational Site

    Topeka, Kansas, 66604

  • GSK Investigational Site

    Walnut Creek, California, 94596

  • GSK Investigational Site

    West Covina, California, 91790

Other trials in United States

Puerto Rico1 site

  • GSK Investigational Site

    San Juan, 00907

Other trials in Puerto Rico

About this study

The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccinesv(RIV).

Read the detailed description

This study is divided into three timepoints:

Epoch 1 - Primary: Day 1 to Day 301 Epoch 2 - Secondary: Day 301 to Day 331 Epoch 3 - Safety follow-up: Day 331 to the end of the study (Day 481 or Day 661). For participants who have not yet reached the 6-month safety follow-up after their last dose at the time Protocol Amendment 7 takes effect, visit 7 takes place on Day 481.

In addition to receiving the study vaccines, infants also receive non-study vaccines such as Diphtheria, tetanus toxoids and acellular pertussis adsorbed vaccine (DTPa, Infanrix) and Haemophilus influenzae type b Conjugate Vaccine (Hib, Hiberix) to minimize disruption to the standard infant vaccination schedule caused by participation in this study.

Participants receive rMenB+OMV NZ (Bexsero) concomitantly with PCV13 (Prevnar13) and other routine infant vaccines (Pediarix, Hiberix, Rotarix, M-M-R II, Varivax) at 2, 4, 6, and 12 months of age. Participants who have received three PCV13 doses before 12 months of age but have not yet received their fourth booster dose receive either PCV13 or PCV20 at 12 months of age (Visit 5).

Being tested
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix
Keywords
Meningitis, Immune response, Sufficiency, Neisseria meningitides, Bexsero
Medical subject headings
Meningococcal Infections, Meningitis, Meningitis, Meningococcal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)Biological

    Bexsero was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.

  • Prevnar13Biological

    Prevnar13 (PCV13) was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.

  • PediarixBiological

    Pediarix (DTPa-HBV-IPV) was administered intramuscularly on Day 1, Day 61, and Day 121.

  • HiberixBiological

    Hiberix (Hib) was administered intramuscularly on Day 1, Day 61, and Day 121.

  • RotarixBiological

    Rotarix (HRV) was administered intramuscularly on Day 1 and Day 61.

  • M-M-R IIBiological

    M-M-R II (MMR) was administered intramuscularly on Day 301.

  • VarivaxBiological

    Varivax (VV) was administered intramuscularly on Day 301.

  • Placebo (saline water)Biological

    Placebo was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.

  • Prevnar 20Biological

    Prevnar 20 (PCV13) was administered intramuscularly as a booster dose on Day 301 group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.

Study groups in NCT03621670
Study groupRoleWhat they receive
MenB+PCV GroupExperimentalInfant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301.
Receives: Biological: Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ); Biological: Prevnar13; Biological: Pediarix; Biological: Hiberix; Biological: Rotarix; Biological: M-M-R II; Biological: Varivax; Biological: Prevnar 20
Placebo+PCV GroupPlacebo comparatorInfant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301.
Receives: Biological: Prevnar13; Biological: Pediarix; Biological: Hiberix; Biological: Rotarix; Biological: M-M-R II; Biological: Varivax; Biological: Placebo (saline water); Biological: Prevnar 20

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1

    Assessed solicited administration site events include injection site tenderness (administration site pain), erythema (redness), swelling and induration. Any solicited administration site events = occurrence of the event regardless of intensity grade. Rotarix was administered orally; therefore, no administration site events were analyzed.

    Measured: Day 1 to Day 7

  2. Number of Participants Reporting Any Solicited Systemic Events After the First Vaccination Administered at Day 1

    Assessed systemic events include change in eating habits, sleepiness, vomiting, diarrhea, irritability, persistent crying, and fever, defined as body temperature greater than or equal to (≥)38.0°C/100.4°F. Any solicited systemic events = occurrence of the event regardless of intensity grade.

    Measured: Day 1 to Day 7

  3. Number of Participants Reporting Any Solicited Administration Site Events After the Second Vaccination Administered at Day 61

    Rotarix was administered orally; therefore, no administration site events were analyzed.

    Measured: Day 61 to Day 67

  4. Number of Participants Reporting Any Solicited Systemic Events After the Second Vaccination Administered at Day 61

    Measured: Day 61 to Day 67

  5. Number of Participants Reporting Any Solicited Administration Site Events After the Third Vaccination Administered at Day 121

    Measured: Day 121 to Day 127

  6. Number of Participants Reporting Any Solicited Systemic Events After the Third Vaccination Administered at Day 121

    Measured: Day 121 to Day 127

  7. Number of Participants Reporting Any Solicited Administration Site Events After the Fourth Vaccination Administered at Day 301

    Measured: Day 301 to Day 307

  8. Number of Participants Reporting Any Solicited Systemic Events After the Fourth Vaccination Administered at Day 301

    Measured: Day 301 to Day 307

  9. Number of Participants With Any Solicited Systemic AEs During the 30 Days After the Fourth Vaccination at Day 301

    Systemic events assessed included rash, parotid/salivary gland swelling, and fever. These systemic adverse events were recorded for 30 days following MMR and VV vaccine administration. Any solicited systemic events = occurrence of the event regardless of intensity grade.

    Measured: Day 301 to Day 330

  10. Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After the First Vaccination Administered at Day 1

    An unsolicited AEs is an AE that is not solicited using a subject diary and that is spontaneously communicated by the parent(s)/LAR(s) who has signed the informed consent or a solicited local or systemic AE that continues beyond the solicited period after vaccination. Any = occurrence of the event regardless of the intensity grade.

    Measured: Day 1 to Day 30

  11. Number of Participants Reporting Any Unsolicited AEs After the Second Vaccination Administered at Day 61

    Measured: Day 61 to Day 90

  12. Number of Participants Reporting Any Unsolicted AEs After the Third Vaccination Administered at Day 121

    Measured: Day 121 to Day 150

  13. Number of Participants Reporting Any Unsolicited AEs After the Fourth Vaccination Administered at Day 301

    Measured: Day 301 to Day 330

  14. Number of Participants Reporting Any SAEs, AEs Leading to Withdrawal, AESIs and MAAEs

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization and that results in disability/incapacity. An AE leading to withdrawal includes any AEs/SAEs collected and recorded from the time of the 1st receipt of study vaccines until study end which are identified as reasons for withdrawal of the participant from the study. AESIs are pre-defined (serious or non-serious) AEs of scientific and medical concern specific to the product or program which might warrant further investigation in order to characterize and understand it. MAAEs includes any AEs that required hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.

    Measured: Day 1 up to study end (Day 481 for participants who have not reached 6-month follow-up at the time of Protocol Amendment 7; Day 661 for all others)

  15. Percentage of Participants With Human Serum Bactericidal Assay (hSBA) Antibody Titers >= Lower Limit of Quantitation (LLOQ) for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4) and M13520 (NHBA)

    Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 60% for each of the M14459, 96217, NZ98/254, M13520 test strain. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

    Measured: At Day 151 (1 month after the third vaccination)

  16. Percentage of Participants With hSBA Titers >= LLOQ Against All Serogroup B Test Strains Combined (Composite Response)

    The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 50% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

    Measured: At Day 151 (1 month after the third vaccination)

  17. Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA) and >= 16 for Strain 96217

    Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥75% for each of the M14459, 96217, NZ98/254, M13520 test strains. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

    Measured: At Day 331 (1 month after the fourth vaccination)

  18. Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp), NZ98/254 (PorA P1.4), and M13520 (NHBA) and >= 16 for Strain 96217 (NadA) (Composite Response Across All Strains)

    The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥65% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

    Measured: At Day 331 (1 month after the fourth vaccination)

  19. Adjusted Geometric Mean Concentrations (GMCs) of Immunoglobubin (IgG) Antibodies Against 13 PCV13 Antigens at 1 Month After Third Vaccination

    The immune response to PCV13 is evaluated by measuring IgG levels using electrochemiluminescence (ECL) assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the third vaccination.

    Measured: At Day 151 (1 month after the third vaccination)

Secondary outcomes (23)

  1. Adjusted GMCs of IgG Antibodies Against 13 PCV13 Antigens at 1 Month After the Fourth Vaccination Administered at Day 301

    The immune response to PCV13 is evaluated by measuring IgG levels using ECL assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the 4th vaccination.

    Measured: At Day 331 (1 month after the fourth vaccination)

  2. Percentage of Participants With Serum Pneumococcal Anti-capsular Polysaccharide IgG >= 0.35 μg/mL

    The immune response to PCV13 is evaluated by measuring the percentage of participants with serum IgG concentrations ≥ 0.35 μg/mL for each of the 13 PCV13 antigens at 1 month after the third and fourth vaccinations.

    Measured: At Day 151 (1 month after the third vaccination) and Day 331 (1 month after the fourth vaccination)

  3. Adjusted GMCs Against 3 Pertussis Antigens (Pertussis Toxin [PT], Pertactin [PRN], Filamentous Hemagglutinin [FHA])

    The immune response to DTaP-HBV-IPV (Pediarix) vaccine is evaluated. IgG concentrations for pertussis antigens (PT, FHA, PRN) are measured at 1 month after the third vaccination and are expressed as international units per millilitre (IU/mL).

    Measured: At Day 151 (1 month after the third vaccination)

  4. Percentage of Participants With Antibodies Concentrations Against Hepatitis B Surface Antigen (AntiHBsAg) >= 10 mIU/mL

    The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Hepatitis B (HepB) antigens are measured at 1 month after the third vaccination.

    Measured: At Day 151 (1 month after the third vaccination)

  5. Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 0.1 IU/mL

    The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for diphtheria (D) and tetanus (T) were measured at 1 month after the third vaccination.

    Measured: At Day 151 (1 month after the third vaccination)

  6. Percentage of Participants With Anti-polyribosyl-ribitol Phosphate (PRP) Concentration >= 0.15 µg/mL and >= 1 µg/mL

    The immune response to Hib vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Haemophilus influenzae type b (Hib) are measured at 1 month after the third vaccination.

    Measured: At Day 151 (1 month after the third vaccination)

  7. Adjusted GMCs for Anti-measles Antibodies

    The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for measles antigens are measured using adjusted GMCs at 1 month after fourth vaccination and are expressed as milli-International Units per milliliter (mIU/mL).

    Measured: At Day 331 (1 month after the fourth vaccination)

  8. Adjusted GMCs for Anti-mumps Antibodies

    The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for mumps antigens are measured using adjusted GMCs at 1 month after fourth vaccination.

    Measured: At Day 331 (1 month after the fourth vaccination)

  9. Adjusted GMCs for Anti-rubella Antibodies

    The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for rubella antigens are measured using adjusted GMCs at 1 month after fourth vaccination.

    Measured: At Day 331 (1 month after the fourth vaccination)

  10. Adjusted GMCs for Anti-Varicella (VV) Antibodies

    The immune response to varicella (VV) vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for varicella antigens are measured using GMCs at 1 month after fourth vaccination.

    Measured: At Day 331 (1 month after the fourth vaccination)

  11. Percentage of Participants With hSBA Antibody Titers >= 5, >= 8 and >=16 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Measured: At Day 151 (1 month after the third vaccination)

  12. Percentage of Participants With hSBA Antibody Titers >= 5 and >= 8 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Measured: At Day 301 (6 months after third vaccination)

  13. Percentage of Participants With hSBA Antibody Titers >= 5 for Each of the Serogroup B Test Strain M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Measured: At Day 331 (1 month after the fourth vaccination)

  14. hSBA Geometric Mean Titers (GMTs) Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Measured: At Day 151 (1 month after the third vaccination), Day 301 (6 months after the third vaccination), and Day 331 (1 month after the fourth vaccination)

  15. hSBA Geometric Mean Ratios (GMRs) Over Pre Fourth Vaccination Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Measured: At Day 331 (1 month after the fourth vaccination) compared to Day 301 (pre-fourth vaccination)

  16. Percentage of Participants With hSBA Antibody Titers >= LLOQ for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Measured: At Day 301 (6 months after the third vaccination) and Day 331 (1 month after the fourth vaccination)

  17. Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    A 4-fold rise in hSBA titers is defined as - if pre-vaccination titer <Limit of Detection (LOD), then a post-vaccination titer >= 4 times the LOD or >= LLOQ, whichever is greater; - if pre-vaccination titer is >= LOD but <LLOQ, then a post-vaccination titer >= 4 times the LLOQ; - if pre-vaccination titer is >= LLOQ, then a post-vaccination titer >= 4 times the pre-vaccination titer, where pre-vaccination titer=pre-4th dose titers (Day 301). This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

    Measured: At Day 331 (1 month after the fourth vaccination) relative to Day 301 (pre-fourth vaccination)

  18. Percentage of Participants With Anti-HBs Antibody Concentrations >= 100 mIU/mL

    Measured: At Day 151 (1 month after the third vaccination)

  19. GMCs for Anti-HBsAg Antibodies

    Measured: At Day 151 (1 month after the third vaccination)

  20. Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 1 IU/mL

    Measured: At Day 151 (1 month after the third vaccination)

  21. GMCs for Anti-diphtheria and Anti-tetanus Antibodies

    Measured: At Day 151 (1 month after the third vaccination)

  22. Percentage of Participants With Anti-polio Type 1, 2 and 3 Neutralization Antibody Titers >= 8

    Measured: At Day 151 (1 month after the third vaccination)

  23. Percentage of Participants With Seroresponse for Anti-Varicella (VV), Anti-measles Virus, Anti-mumps Virus and Anti-rubella Virus Antibodies

    Seroresponse is defined as post-vaccination anti-VZV virus, anti-measles virus, anti-mumps virus and anti-rubella virus antibody concentration >= a protective threshold among participants who were seronegative (antibody concentration < assay cut-off) before vaccination.

    Measured: At Day 331 (1 month after the fourth vaccination)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2018
  2. Study start27 Jul 2018
  3. Primary completion27 Dec 2024
  4. Study completion27 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
1,196 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03621670
Sponsor's protocol ID
205239
Other IDs
2016-003268-37, V72_57, 2016
Status last verified
Jul 2026
First submitted
10 Jul 2018
Last updated
20 Aug 2026
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: IPD for this study will be made available via the Clinical Study Data Request site.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in